© 2020 MJH Life Sciences and Formulary Watch. All rights reserved.
Cardiovascular
Blood pressure drug recalls soar
March 04, 2019
The recalls of a widely used hypertension blood drug due to carcinogenic impurities are expanding.
Popular blood pressure drug recalled
November 06, 2018
A pharma maker is voluntarily recalling several lots of a major heart medication. Here’s why.
FDA denies claims for Zetia, Vytorin
February 17, 2016
FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
FDA: Slightly elevated risk of cardiovascular, cerebrovascular issues with Xolair
September 29, 2014
An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug omalizumab (Xolair, Genentech) than in those who were not treated with omalizumab. As a result, FDA has added information about these potential risks to the drug label.
[BLOG] The acute coronary syndrome pipeline: Novel therapies targeting unmet needs in niche patient populations
August 19, 2014
Not surprisingly, the treatment costs associated with ACS and its various comorbidities are astoundingly high.
ADA: Canola oil can help control blood glucose in people with type 2 diabetes
June 17, 2014
Unhydrogenated, unsaturated vegetable oils, such as canola oil, can have health advantages when included in as part of a low-glycemic index (GI) diet in people with type 2 diabetes, according to research presented at American Diabetes Association Scientific Sessions in San Francisco, and published in Diabetes Care.
Novartis heart failure drug fails to win FDA approval
May 19, 2014
FDA has decided not to approve acute heart failure drug serelaxin (Novartis).
FDA approves Pradaxa for treatment, reduction in risk of recurrence of DVT, PE
April 09, 2014
FDA approved dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5 to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.
ACC: Bivalirudin associated with reductions in cardiac death, major bleeding in STEMI patients undergoing PCI
April 03, 2014
Compared to a combination of heparin and a glycoprotein (GP) IIb/IIIa inhibitor, use of bivalirudin (Angiomax) is associated with significant absolute reductions in risk for cardiac death and major non-coronary artery bypass graft (CABG) bleeding, according to data presented at the American College of Cardiology 63rd Annual Scientific Session (ACC.14), in Washington, D.C.